Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

October 30, 2028

Study Completion Date

December 31, 2028

Conditions
Pituitary AdenomaMRIRCT
Interventions
DRUG

Cabergoline 0.5 MG

Cabergoline (Dostinex ®) 0.5 mg/tablet. Cabergoline will be given orally 1mg/week (Day1-14), 2mg/week (Day15-end of the study).

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital Beihu Branch

OTHER

collaborator

National Taiwan University

OTHER

collaborator

National Taiwan University Hospital Hsin-Chu Branch

OTHER

collaborator

National Taiwan University Hospital, Yun-Lin Branch

OTHER

lead

National Taiwan University Hospital

OTHER